The pharmacogenomics of drug resistance to protein kinase inhibitors.

about

Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.

P2860

Q33828559-23DD1D84-E24A-4BD7-9155-FD89CFF69FD5 Q49184931-DB2CC520-F8FB-44C2-AB3B-E9F32C8BC611

P2860

The pharmacogenomics of drug resistance to protein kinase inhibitors.

Item

http://www.wikidata.org/entity/Q38952751

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The pharmacogenomics of drug resistance to protein kinase inhibitors.

@en

type

Item

label

The pharmacogenomics of drug resistance to protein kinase inhibitors.

@en

prefLabel

The pharmacogenomics of drug resistance to protein kinase inhibitors.

@en

P1476

The pharmacogenomics of drug resistance to protein kinase inhibitors

@en

P2093

Howard L McLeod

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Cancer drug resistance: redox resetting renders a way

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

P304

28-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUP.2016.06.008

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nancy K Gillis

P577

2016-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27620953

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

5022787

http://www.w3.org/2001/XMLSchema#string

The pharmacogenomics of drug resistance to protein kinase inhibitors.

about

P2860

P2860

The pharmacogenomics of drug resistance to protein kinase inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932